Fresenius announced that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.

These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia® (denosumab) and Xgeva® (denosumab), respectively.

Conexxence is available in a 60 mg/mL single-use prefilled syringe. Bomyntra is available in a 120 mg/1.7 mL vial and a 120 mg/1.7 mL single-use prefilled syringe.

“Fresenius Kabi is very pleased to continue the consistent launches of new biosimilars for U.S. patients, providers and payors,” said Dr. Sang Jin Pak, President Fresenius Kabi Biopharma. “Access to high-quality biological medicines creates the opportunity to provide more affordable therapies to patients and as our biosimilar portfolio expands, we will be able to provide access for even more patients.”

Earlier this year, Fresenius announced Fresenius Kabi reached a global settlement with Amgen concerning its denosumab biosimilars.